Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (151-160 of 174) with videos related to

Pageof 18
Sort By:
Blood Cancer Discovery|October 18, 2021
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersMalin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Research Square|June 17, 2024
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple MyelomaMalin Hultcrantz, Hani Hassoun, Neha Korde, et al.
Blood Cancer Discovery|October 15, 2021
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersMalin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 15, 2022
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trialsKenneth Cornetta, Jing Yao, Kimberley House, et al.
Blood Cancer Journal|September 19, 2024
Colesevelam for lenalidomide associated diarrhea in patients with multiple myelomaMalin Hultcrantz, Hani Hassoun, Neha Korde, et al.
Transplantation and Cellular Therapy|March 17, 2021
Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent WavesMariam T Nawas, Gunjan L Shah, Darren R Feldman, et al.
American Journal of Hematology|April 26, 2022
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experienceMeera Mohan, Melody Renee Becnel, Urvi A Shah, et al.
Pageof 18

Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
Blood Cancer Discovery|October 18, 2021
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersMalin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Research Square|June 17, 2024
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple MyelomaMalin Hultcrantz, Hani Hassoun, Neha Korde, et al.
Blood Cancer Discovery|October 15, 2021
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersMalin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 15, 2022
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trialsKenneth Cornetta, Jing Yao, Kimberley House, et al.
Blood Cancer Journal|September 19, 2024
Colesevelam for lenalidomide associated diarrhea in patients with multiple myelomaMalin Hultcrantz, Hani Hassoun, Neha Korde, et al.
Transplantation and Cellular Therapy|March 17, 2021
Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent WavesMariam T Nawas, Gunjan L Shah, Darren R Feldman, et al.
American Journal of Hematology|April 26, 2022
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experienceMeera Mohan, Melody Renee Becnel, Urvi A Shah, et al.
Pageof 18